Featured Articles

1. How To Avoid GMP Manufacturing Pitfalls 4/10/2026

   Common GMP pitfalls stem from poor scalability, late regulatory planning, weak tech transfer, unsuitable hosts, and inadequate quality systems, delaying biologics production timelines and budgets.

2. Licensed Vs. Unlicensed Cell Lines In Biologics Development 3/19/2026

   Choosing licensed vs. unlicensed cell lines impacts development speed, cost, flexibility, and long‑term control, making early strategic evaluation key to efficient biologics development.

3. Understanding Drug Substance and Product Manufacturing 3/19/2026

   Understanding drug substance vs. drug product responsibilities helps avoid regulatory issues, technical risks, and delays while improving planning, scalability, and GMP‑compliant execution.

4. Five Tips For A Successful Tech Transfer To A CDMO 3/19/2026

   Successful tech transfer depends on solid documentation, early teamwork, clear expectations, proactive risk planning, and experienced partners to keep execution smooth and projects moving on schedule.